Join us for an intermediate-level (100–200) musculoskeletal (MSK) webinar focused on the interventional treatment of malignant and metastatic bone lesions in both the axial and appendicular skeleton. Additionally, the presenters will be covering techniques like ablation, cementation, and embolization. 

Moderator: 

Jason Levy, MD, FSIR | Interventional Radiology | Northside Radiology Associates

Speakers: 

Jason Levy MD, FSIR | Interventional Radiology | Northside Radiology Associates
Muneeb Ahmed, MD  | Interventional Radiology |Beth Israel Deaconess Medical Center
Brandon Key. MD | Vascular & Interventional Radiology | Froedtert & Medical College of Wisconsin

Session 2: Interventional Oncology: Transarterial Therapies Primer

Moderators: Kirema Garcia-Reyes, MD (IO) and Adam Burgoyne, MD, PhD (Medical Oncology)

Chemoembolization: Current State of the Science | Kelvin Hong, MBBCH

Radioembolization: Radiation Basics of Y90 | S. Cheenu Kappadath, PhD, FAAPM

Resin Microsphere Dosimetry
Marnix Lam, MD, PhD
Glass Microsphere Dosimetry
Christopher D. Malone, MD


Session 3: Biomarkers
Moderators: Terence P. Gade, MD, PhD, (IO) and Amit Singal, MD (Medical Oncology)

Keynote: How Does Immunotherapy Fit with Locoregional Therapies
Amit Singal, MD

Immunological Effects of Local Therapies in the Tumor Microenvironment
Rony Avritscher, MD
Unraveling Mechanisms of Resistance to Immunotherapy in HCC

Luciane Tsukamoto Kagohara, PhD

Imaging Biomarkers of Response to Immuotherapy in Liver Cancer
Aliya Qayyum, MD

Minimal Residual Disease after TACE
 Renumathy Dhanasekaran, MD

Session 4: Sequencing
Moderators: Thomas Helmberger, MD, (IO) and Amit Singal, MD (Medical Oncology)

Clinical Rationale for Different Sequencing Strategies
Tim F. Greten, MD

Impact of Various Interventional Modalities on Sequencing Rationale
 Terence P. Gade, MD, PhD

Tumor Heterogeneity and Combination Therapies
Luciane Tsukamoto Kagohara, PhD

Managing Adverse Event of Combination Therapies
Adam Burgoyne, MD, PhD

Friday, 6 June

Session 5: Combination Therapies (IO + IO)
Moderators: Edward Kim, MD, FSIR, (IO) and Stephen L. Chan, MBBS, MD, FRCP, FHKCP, FHKAM (Hepatology)

EMERALD-1 and LEAP-012
Lingling Du, MD

Will Combination Therapy Impact My Practice: Oncology Perspective
Stephen L. Chan, MBBS, MD, FRCP, FHKCP, FHKAM

Will Combination Therapy Impact My Practice: Hepatology Perspective
Anjana Pillai, MD

Will Combination Therapy Impact My Practice: Surgical Perspective
Myron E. Schwartz, MD

TARE: Ongoing Trials and IR Perspective of EMERALD-1 and LEAP-12
Christopher D. Malone, MD

Session 6: TARE or...
Moderators: Robert J. Lewandowski, MD, FSIR, Nora Tobori, MD

Solitary HCC: Ablative SBRT
Stanley Liauw, MD

Solitary HCC: Radiation Segmentectomy
Beau Toskich, MD

BTC: HAI Pump
Alice Wei, MD, MSc

BTC: TARE
William Rilling, MD, FSIR

Multifocal Bilobar HCC: Systemic Therapy Alone
William P. Harris, MD

Multifocal Bilobar HCC: TACE
Kelvin Hong, MBBCH

Multifocal Bilobar HCC: TARE
Nima Kokabi, MD

Session 7: Practical y90
Moderators: Siddharth A. Padia, MD, and Robert J. Lewandowski, MD, FSIR

Radiation Lobectomy
Robert J. Lewandowski, MD, FSIR

Flow Diversion: What is it and Why?
Beau Toskich, MD

Extra-Hepatic Supply
Kirema Garcia-Reyes, MD

High Lung Shunts
John D. Louie, MD

Lessons Learned from the European Perspective of TARE
Thomas Helmberger, MD

Lessons Learned from the Korean Perspective of TARE
 Jin Woo Choi, MD, PhD

Vascular Invasion in the Era of Immunotherapy
Siddharth A. Padia, MD

Session 8: Multidisciplinary Case Review 1: Curative Intent
Moderator: Riad Salem, MD, MBA

HCC: Solitary HCC Beyond T2 with Elevated AFP
Myron E. Schwartz, MD

HCC: Multi-focal within Downstaging Criteria
Kelvin Hong, MBBCH

CRC Transplant Downstaging
Daniel B. Brown, MD, FSIR

HCC: Unilobar VP3 Invasion
Stephen L. Chan, MBBS, MD, FRCP, FHKCP, FHKAM
Stanley Liauw, MD

Session 9: Multidisciplinary Case Review 2: Palliative Intent
Moderator: Siddarth A. Padia, MD

HCC: Infiltrative HCC with Elevated AFP
Nora Tabori, MD

HCC: Large Solitary Tumor
Anjana Pillai, MD

HCC: Unilobar with Pulmonary Mets
Jin Woo Choi, MD, PhD

BTC: Recurrence Post-resection
Beau Toskich, MD
William P. Harris, MD;
Alice Wei, MD
Stanley Liauw, MD

SIO’s 100-200 level Lung focused webinar explores the cutting-edge developments in lung treatment, including the emerging role of Pulse Electric Field (PEF) technology as a non-thermal ablation technique. We will cover the theoretical concepts behind PEF, review current research efforts, and provide a detailed look at its clinical applications in lung treatment. The session is designed to offer attendees a comprehensive understanding of the potential of PEF, from scientific principles to real-world implications and will offer a Q & A discussion at the end. This webinar was recorded in May, 2025. 

Moderators:

Vladimir Sheynzon, MD | Columbia University College of Physicians and Surgeons
Gaby Gabriel, MD | University of Kentucky/Markey Cancer Center

Faculty:

William Moore, MD | Professor, Department of Radiology at NYU Grossman School of Medicine
David Hirschl, MD | Assistant Professor Radiology Columbia University Irving Medical Center

This bundle contains all of the lecture recordings from SIO's 2025 Annual Meeting in Las Vegas, Nevada (January 30 - February 3).

An online, 12-module course focused on basic PI competencies designed by SIO alongside CRO experts and interventional oncology Principal Investigators (PIs) who understand the complexities of completing a successful multicenter clinical trial.

Learners who complete the course and pass the quiz will earn an SIO certificate of completion identifying them as a qualified PI.  

The certificate of completion will be valid for up to three years with an option to retest to maintain the certificate.

1. Opening Remarks, presented by Jack Jennings, MD, PhD, FSIR, Washington University St. Louis and Sean M. Tutton, MD, FSIR, FCIRSE, UCSD Health
2. Embolization, presented by Muneeb Ahmed, MD, FSIR, Beth Israel Deaconess Medical Center/Harvard Medical School
3. BVNA, presented by Joshua A. Hirsch, MD, Massachusetts General Hospital
4. MSK Biopsy and Imaging, presented by Connie Y. Chang, MD, Massachusetts General Hospital/Harvard Medical School
5. MSK IO Private Practice, presented by Jason R. Levy, MD, FSIR, Northside Hospital Atlanta
6. Spine Tumors and Ablation, presented by Allan L. Brook, MD, FACR, FSIR, Montefiore Einstein
7. Extra-spinal Tumors and Ablation, presented by Damian E. Dupuy, MD, FACR, Cape Cod Hospital/Brown University
8. Pelvic Fixation, presented by Matthew J. Scheidt, MD, FSIR, Froedtert and the Medical College of Wisconsin
9. Desmoids and Soft Tissue, presented by Peter J. Littrup, MD, University of Rochester
10. Thermoprotective Techniques, presented by Resten Imaoka, MD, Washington University St. Louis

This two-day course is your comprehensive guide to radioembolization. Dive into the latest data and techniques by reviewing slides from our expert faculty:

Thursday, 6 June: Data and Discussion 

Session 1 - Fundamentals (100)

1.1 What Do I Need to Know as an IR in Oncology, presented by Daniel B. Brown, MD, FSIR, Vanderbilt University Medical Center

1.2 Principles of Glass and Resin Microspheres 

1.3 Absorbed Dose and Specific Activity

1.4 Optimizing Patient Selection: HCC vs Metastatic Disease

1.5 Patient Management: Clinical and Imaging

Session 2 - Data Deep Dive: Early Stage HCC (100-200)

2.1 Why I Choose Glass Microspheres for RadSeg

2.2 Why I Choose Resin Microspheres for RadSeg

2.3 Is TARE Superior in Bridging/Downstaging Patients?

2.4 Role of Radiation Lobectomy in HCC

Session 3 - Data Deep Dive: Intermediate & Advanced HCC (100-200)

3.1 TARE or TACE in Intermediate Stage HCC?

3.2 Expanding Role for Systemic Therapy in HCC: Moving to Intermediate Stage and Combinations

3.3 Is TARE Still Relevant in Advanced Stage HCC?

3.4 Checkpoint Inhibitor Review for Advanced Stage: Potential for Combination?

Session 4 - Everything Else (100-200)

4.1 mCRC: When to Use TARE Amongst Systemic Therapy

4.2 Cholangiocarcinoma: TARE/SBRT or Systemic

4.3 mNET: Is TARE Making a Comeback?

4.4 Current Status of Data and Ongoing Trials in Glass Microspheres

4.5 Current Status of Data and Ongoing Trials in Resin Microspheres

4.6 Current Status of Data and Ongoing Trials in Radio-opaque Glass Microspheres

Friday, 7 June: Tips, Tricks & Techniques 

Session 5: Logistics (100)

5.1 What You Need to Build a Y90 Practice

5.2 Coding and Reimbursement 

5.3 Volumetry, Prescribing a Dose, and Order for Resin Microspheres

5.4 Volumetry, Prescribing a Dose, and Order for Glass Microspheres

5.5 TARE in Private Practice and OBLs

5.6 Review of NRC Safety Events in Radioembolization

Session 6: Case Studies (200-300)

6.1 Radiation Segmentectomy

6.2 Radiation Lobectomy

6.3 HCC with Portal Vein Invasion

Session 7: Dosimetry Case Studies (200-300

7.1 High Lung Shunt

7.2 Multifocal HCC

7.3 Multifocal mCRC

7.4 Cholangiocarcinoma

Session 8: Technical Challenges in Radioembolization (300)

8.1 Flow Diversion and Angiosome Modulation: Balloons, Coils, Plugs, and Gelfoam

8.2 Radioembolization of Tumors with Extra-hepatic Supply

8.3 When and How to Use Multi-vial, Multi-catheter Delivery

8.4 When Not to Perform TARE

SIO2022 Conference Recordings

This recording is part of the SIO2022 Conference Recordings Bundle. Click here to purchase the full bundle and save!